May 1st 2025
Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2
November 10th 2021Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.
Partnership Aims to Accelerate and Improve Smart Bioprocess Development Solutions
October 29th 2021Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.